GKOS logo

GKOS Glaukos Corporation

New York Stock Exchange · Medical - Devices · Healthcare

$237.31
-0.79 (-0.33%)

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surg…

Market Cap: $14.05Bwww.glaukos.com

Price

No data yet.

Social Signal Score

58
5d
75
1 mentions
—
30d
53
7 mentions
—
60d
53
19 mentions
—
90d
53
19 mentions
—
news: 12 · marketaux: 2 · rss: 5

Analyst Ratings

25 analysts
Buyconsensus
Strong Buy 0Buy 18Hold 6Sell 1Strong Sell 0
Avg price target$225.55-5.0%
Low $150Median $240High $255
Current Consensus

Revenue

$211.03M+536.17%
$31.56M$91.38M$151.21M$211.03M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.82
$-0.90–$-0.70
11 analysts
FY2026
$0.67
$0.44–$0.90
8 analysts
FY2027
$1.40+107% YoY
$1.05–$2.38
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Thomas William Burns
Sector
Healthcare
Industry
Medical - Devices
Employees
1,094
Beta
0.69
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
31.44
www.glaukos.com